Skip to main
SGHT
SGHT logo

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc. is positively positioned for growth, largely due to its Surgical Glaucoma segment, which is expected to sustain its expansion in alignment with the overall minimally invasive glaucoma surgery (MIGS) market. The company anticipates stronger revenue growth driven by faster market share gains in MIGS and quicker adoption of its TearCare System, while also making progress toward achieving profitability. Furthermore, revenue projections for 2025 and 2026 are forecasted at $75 million and $82 million, respectively, alongside improved earnings per share expectations, indicating a strengthening financial outlook.

Bears say

Sight Sciences Inc. maintains a revenue guidance of $72-76 million for 2025, with expectations of a mid-single-digit percentage decline in the Surgical Glaucoma segment for the third quarter of 2025. The company faces significant risks, including escalating competition in minimally invasive glaucoma surgery (MIGS), delayed insurance coverage progress for its TearCare product, and continued high quarterly cash burn rates. Additionally, management has revised its adjusted operating expenditure forecast downward to $95-99 million from an earlier estimate of $101-105 million, although this reduction reflects anticipated savings from a restructuring initiative.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.